Pivotal failure triggers job cuts at San Diego-based Tocagen
Tocagen is circling the drain, following the crushing late-stage failure of its experimental brain cancer therapy last month. On Thursday, the San Diego-based company slashed its workforce by 65%.
Its two-part therapy was being tested in patients with recurrent high-grade glioma undergoing resection in the Toca 5 study. On average, patients on the Tocagen regimen actually did not live as long as those given standard treatment (11.1 months median compared to 12.2 months). In addition, the company’s therapy hit a hazard ratio of 1.06, reflecting an increased risk to patients, along with an unsavory p-value of 0.6154.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.